Biomedicines · 2025
Long-Term Clinical and Endoscopic Outcomes of Crohn's Disease Following Liver Transplantation: A Multicenter Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ar Ebru, Solomonidou Irini, Lenzen Henrike, Wiestler Miriam, Veltkamp Claudia, Willuweit Katharina, Rashidi-Alavijeh Jassin, Schmidt Hartmut H, Vollenberg Richard, Tepasse Phil-Robin, Trebicka Jonel, Tischendorf Stefanie, Elfers Carsten, Hamesch Karim, Bokemeyer Arne
Аннотация
Patients with Crohn's disease (CD) may require liver transplantation (LT) due to advanced liver diseases, including primary sclerosing cholangitis (PSC), autoimmune hepatitis, or other etiologies. However, data on CD activity and the use of advanced therapies following LT are limited. This study aimed to assess CD activity before and after LT and to evaluate the use of advanced therapies in this setting. Methods: In this multicenter retrospective cohort study, we analyzed 40 patients with CD who underwent LT between 2000 and 2022 at four university hospitals in Germany. Clinical and endoscopic disease activity, as well as the use of advanced therapies, were evaluated before and after transplantation. Results: Before LT, 89.7% of patients were in clinical remission, which remained stable after LT (85.7%; p = 0.650). Nevertheless, 22.6% of these patients demonstrated moderate to severe mucosal inflammation on endoscopy during long-term follow-up. The use of advanced therapies remained low after transplantation (pre-LT: 11.7%, post-LT: 7.5%; p = 0.532) even among those with endoscopic disease activity. Conclusions: Although clinical remission of CD is usually maintained following LT, endoscopic evidence of persistent mucosal inflammation is common and may be underrecognized. Despite this, advanced therapies are not frequently used in the post-transplant setting. These findings suggest that individualized treatment strategies are needed to address subclinical disease activity while balancing therapeutic effectiveness with transplant-specific risks.